A Study of LY2624587 in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Study CXBA is a multicenter nonrandomized, dose escalation, open-label, Phase 1 study of
intravenous LY2624587 in patients with advanced or metastatic cancer for which no treatment
of higher priority exists.